SHARE

Sanofi to buy Dren Bio’s immunology unit

The healthcare group has reached an agreement to acquire biopharmaceutical company Dren Bio’s autoimmune disease treatment, DR-0201. The acquisition includes an upfront payment of $600m, with potential future payments totaling $1.3bn.

Certification Note

Certified B Corporation” is a trademark licensed by B Lab, a private non-profit organization, to companies like ours that have successfully completed the B Impact Assessment (“BIA”) and therefore meet the requirements set by B Lab for social and environmental performance, accountability, and transparency. It is specified that B Lab is not a conformity assessment body as defined by Regulation (EU) No 765/2008, nor is it a national, European, or international standardization body as per Regulation (EU) No 1025/2012. The criteria of the BIA are distinct and independent from the harmonized standards resulting from ISO norms or other standardization bodies, and they are not ratified by national or European public institutions.